STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3270 by analyst upside · 2026-06-27
MANE
Veradermics, Incorporated
Healthcare · Market Cap $5B · P/E 0x
ANALYST PRICE TARGET
+4.7%
implied upside to consensus target
Current Price $126.89
Consensus Target $132.8
Bull Target $138.0
Bear Target $120.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
5
Hold
0
Sell
0
52-Week Low $32.0
52-Week High $128.1
YTD Return +236.1%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) N/A
Forward P/E -41.8x
EPS (TTM) $-2.65
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $32.0
52-Week High $128.1
Current Price $126.89
Bear Target $120.0
Bull Target $138.0
● Now $126.89 ● Target $132.8
TRADING DATA
Avg Volume 599K
YTD Return +236.1%
Analyst Count 5
Consensus Buy
Upside to Target +4.7%
Last Updated 2026-06-27

ANALYST SUMMARY

Veradermics, Incorporated (MANE) is currently trading at $126.89 with a Wall Street consensus price target of $132.8, implying potential upside of 4.7% over the next 12 months. 5 analysts currently cover MANE, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $138.0, while the most cautious has a target of $120.0.

MANE operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 236.1% year-to-date and is currently trading near the upper end of its 52-week range of $32.0 – $128.1.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for MANE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

LifeSci Capital ● Initiated
Outperform 2026-06-16 Building track record
Needham ● Initiated
Buy 2026-06-02 20% win rate (5 calls)
Citigroup — Reiterated
Buy → Buy 2026-05-18 Building track record
Leerink Partners — Reiterated
Outperform → Outperform 2026-04-22 29% win rate (7 calls)
Cantor Fitzgerald ● Initiated
Overweight 2026-03-02 40% win rate (10 calls)
Citigroup ● Initiated
Buy 2026-03-02 Building track record
Leerink Partners ● Initiated
Outperform 2026-03-02 29% win rate (7 calls)
Jefferies ● Initiated
Buy 2026-03-02 50% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
68
out of 100
Coverage depth
14/30
Consensus clarity
27/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →